Medicine profile
Amycretin
Investigational single-molecule GLP-1 and amylin agonist in subcutaneous and oral formulations; results are formulation-specific.
- Generic name
- Amycretin
- Also known as
- NNC0487-0111
- Sponsor and licensing
- Novo Nordisk (originator)
- Mechanism
- GLP-1 and amylin receptor agonist (single molecule)
- Molecular type
- Peptide (mechanism and molecular type are recorded separately: GLP-1 activity does not make a medicine a peptide)
Brands, routes and formulations
Amycretin (no brand yet)
subcutaneous 路 once-weekly injection
No verified approval recorded for this product.
Amycretin (no brand yet)
oral 路 once-daily tablet
No verified approval recorded for this product.
Regulatory status by jurisdiction
Authorisation, launch and funded access are three different things and are shown separately. "Not recorded" means GLPInfo has not verified an event, not that nothing has happened.
| United States (FDA) | United Kingdom (MHRA) | European Union (EMA / EC) | |
|---|---|---|---|
| Regulatory authorisation | Not recorded | Not recorded | Not recorded |
| Commercial launch | Not recorded | Not recorded | Not recorded |
| Funded access | Not recorded | Not recorded | Not recorded |
Development timeline
Amycretin
No verified events recorded yet.
Dashed line: today, 13 Sep 2026. Future windows are conditional. Approval, launch and funded access are separate milestones.
Select a marker to open its record in the pipeline view, which has the detail panel and the accessible list.
Next milestone and forecast rationale
No forecast is published for Amycretin. One appears only when there is a responsible range with assumptions and sources.
Trial evidence
| Trial | Phase | Population | Duration | Results |
|---|---|---|---|---|
| Amycretin subcutaneous phase 1b/2a (obesity)Novo Nordisk 路 subcutaneous, once weekly (dose escalation up to 60 mg) | 1b/2a | Adults with overweight or obesity (BMI 27 or more) without diabetes; the workbook's 125-participant figure is unverified | 36 weeks | On file from the research workbook; withheld until the primary publication or registry record is attached. |
GLPInfo does not rank unrelated trials against each other or quote "weight loss per week": populations, durations and methods differ and weight change is not linear. Results appear here per trial and dose arm, with comparator, endpoint and source, once cited.
Known limitations and official labels
This profile is assembled from the regulatory records and sponsor statements GLPInfo has verified; it is not a complete review of Amycretin. The current official label in each jurisdiction is the authority on indications, populations and safety.
Review date and correction history
Records last checked 13 Sep 2026. No corrections have been made to the records on this profile; every record is at version 1. Report a correction.
Related news
No news articles yet for Amycretin.